Screening for atrial fibrillation
63 results
1 - 63
Screening for atrial fibrillation 
Systematic screening for the detection of atrial fibrillation
Screening for atrial fibrillation in primary care is not effective (VITAL-AF)- USPSTF 2022 concludes evidence is insufficient to recommend screening for asymptomatic atrial fibrillation (I statement)
- Screening high-risk patients for atrial fibrillation with implantable loop recorder does not prevent stroke or systemic emboli (LOOP)
- Prevention of atrial fibrillation
- Automated devices detect only 67% to 83% of patients with atrial fibrillation
- The prognosis is similar for adults with symptomatic versus asymptomatic atrial fibrillation
- ACC/AHA guidelines for the diagnosis and management of atrial fibrillation
- USPSTF 2018: insufficient evidence to recommend screening for AFib with ECG (I statement)
- Symptoms of arrhythmia and examination of an arrhythmia patient
- Treatment approach for atrial fibrillation: rate control or rhythm control?
- Concomitant atrial fibrillation surgery for people undergoing cardiac surgery
- Hyperthyroidism as a risk factor for atrial fibrillation
- Hypertrophic cardiomyopathy
- Lower risk of atrial fibrillation with addition of vasopressin to catecholamines for treatment of shock
- Intensive cardiovascular screening has little benefit in older men (DANCAVAS)
- Electrical cardioversion
- AHA guideline for secondary stroke prevention
- Clinical service organisation for adults with atrial fibrillation
- Screening for thyroid disease and treatment of subclinical hypothyroidism
- Low-intensity warfarin may be inferior to standard-intensity warfarin for preventing VTE after joint arthroplasty
- Exercise‐based cardiac rehabilitation for adults with atrial fibrillation
- Transcatheter aortic valve implantation versus surgical aortic valve replacement for severe aortic stenosis in people with low surgical risk
- Zoledronic acid reduces asymptomatic fractures but not clinical ones in men
- Evaluation of thrombophilia
- Empagliflozin reduces hospitalization for heart failure with preserved ejection fraction (NNT = 59 per year), but not mortality outcomes (EMPEROR-Preserved)
- Ambulatory ECG monitoring
- Anticoagulation versus placebo for heart failure in sinus rhythm
- Antithrombotic treatment after stroke due to intracerebral haemorrhage
- Home‐based versus centre‐based cardiac rehabilitation
- Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
- Interrupted versus uninterrupted anticoagulation therapy for catheter ablation in adults with arrhythmias
- Warfarin therapy